FXR和HSD17B13的双重调节剂：在MASH中振兴FXR治疗

IF 7.3 1区医学 Q1 CHEMISTRY, MEDICINAL Journal of Medicinal Chemistry Pub Date : 2025-03-05 DOI:10.1021/acs.jmedchem.5c00539

Changhong Wei, Yun Liu, Zhiming Yan, Jing Han, Neng Jiang

{"title":"FXR和HSD17B13的双重调节剂：在MASH中振兴FXR治疗","authors":"Changhong Wei, Yun Liu, Zhiming Yan, Jing Han, Neng Jiang","doi":"10.1021/acs.jmedchem.5c00539","DOIUrl":null,"url":null,"abstract":"Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound <b>6</b>, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"53 1","pages":""},"PeriodicalIF":7.3000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH\",\"authors\":\"Changhong Wei, Yun Liu, Zhiming Yan, Jing Han, Neng Jiang\",\"doi\":\"10.1021/acs.jmedchem.5c00539\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound <b>6</b>, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.\",\"PeriodicalId\":46,\"journal\":{\"name\":\"Journal of Medicinal Chemistry\",\"volume\":\"53 1\",\"pages\":\"\"},\"PeriodicalIF\":7.3000,\"publicationDate\":\"2025-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Medicinal Chemistry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1021/acs.jmedchem.5c00539\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00539","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

摘要

FXR和HSD17B13的双重调节为治疗代谢功能障碍相关脂肪性肝病（MAFLD）和代谢功能障碍相关脂肪性肝炎（MASH）提供了一种有前景的策略。化合物6是FXR和HSD17B13的开创性双调节剂，在各种mld模型中验证了显著增强肝功能，减少炎症和纤维化的概念。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Dual Modulator of FXR and HSD17B13: Revitalizing FXR Therapies in MASH

Dual modulation of FXR and HSD17B13 presents a promising strategy for treating metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH). Compound 6, a groundbreaking dual modulator of FXR and HSD17B13, validates the concept of significantly enhancing liver function, reducing inflammation and fibrosis across various MAFLD models.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.